277 related articles for article (PubMed ID: 7838435)
21. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
[TBL] [Abstract][Full Text] [Related]
22. Clinical experience with a triphasic oral contraceptive ('Trinordiol') in young women.
Gaspard UJ; Deville JL; Dubois M
Curr Med Res Opin; 1983; 8(6):395-404. PubMed ID: 6406157
[TBL] [Abstract][Full Text] [Related]
23. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
Carr BR; Ory H
Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
[TBL] [Abstract][Full Text] [Related]
24. Prescription contraceptives: countering the risks.
Ruggiero RJ
Am Pharm; 1985 Sep; NS25(9):32-7. PubMed ID: 4050670
[TBL] [Abstract][Full Text] [Related]
25. Benefits and risks of oral contraceptive use.
Williams RS
Postgrad Med; 1992 Nov; 92(7):155-7, 161-2, 168-71. PubMed ID: 1437913
[TBL] [Abstract][Full Text] [Related]
26. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
Notelovitz M; Kitchens CS; Khan FY
Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
[TBL] [Abstract][Full Text] [Related]
27. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
28. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
[TBL] [Abstract][Full Text] [Related]
29. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
[TBL] [Abstract][Full Text] [Related]
30. Oral contraceptives.
Maclennan AH
Curr Ther (Seaforth); 1987 Dec; 28(12):113-22. PubMed ID: 12317413
[TBL] [Abstract][Full Text] [Related]
31. Oral contraceptives and cardiovascular risk. Taking a safe course of action.
Derman RJ
Postgrad Med; 1990 Sep; 88(4):119-22. PubMed ID: 2204902
[TBL] [Abstract][Full Text] [Related]
32. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
[TBL] [Abstract][Full Text] [Related]
33. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
[TBL] [Abstract][Full Text] [Related]
34. Update on the metabolic effects of steroidal contraceptives.
Sondheimer SJ
Endocrinol Metab Clin North Am; 1991 Dec; 20(4):911-23. PubMed ID: 1778182
[TBL] [Abstract][Full Text] [Related]
35. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
Crook D; Godsland IF; Wynn V
Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
[TBL] [Abstract][Full Text] [Related]
36. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L
Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417
[TBL] [Abstract][Full Text] [Related]
37. A norgestimate-containing oral contraceptive: review of clinical studies.
Kafrissen ME
Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
[TBL] [Abstract][Full Text] [Related]
38. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
Akerlund M; Røde A; Westergaard J
Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
[TBL] [Abstract][Full Text] [Related]
39. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
Norris LA; Bonnar J
Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
[TBL] [Abstract][Full Text] [Related]
40. On the epidemiology of oral contraceptives and disease.
Prentice RL; Thomas DB
Adv Cancer Res; 1987; 49():285-401. PubMed ID: 3314396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
